系统性巨细胞瘤的第七因子缺乏与相关的骨髓质新型瘤
Giorgio Rosati1, Sofia Camerlo1, Alessandro Fornari2
1Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy.
Hematology reports
|March 27, 2024
概括
这项研究详细介绍了一例罕见的获得性第七因子缺乏症病例,该病例发生在患有真多细胞血症和全身性巨细胞瘤症的患者身上. 这种缺陷在癌症治疗中得到解决,这表明血液瘤和出血障碍之间存在联系.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 凝血障碍 凝血障碍 凝血障碍
背景情况:
- 第七因子 (FVII) 缺乏症是一种罕见的出血障碍,既是先天性,又是获得性.
- 获得的FVII缺乏通常与维生素K缺乏,肝病或抑制剂有关.
- 孤立获得的FVII缺乏症不常见,通常与自身抗体有关.
研究的目的:
- 描述一个独特的同时出现全身性巨细胞瘤和FVII缺乏症的病例,该病例发生在患有真多细胞血症的患者身上.
- 在此背景下调查FVII缺陷的原因及其对治疗的反应.
- 探索系统性巨细胞瘤与血液瘤 (SM-AHN) 和获得的FVII缺陷之间的潜在关联.
主要方法:
- 病例报告详细介绍了一名患有真多细胞血症,全身性巨细胞瘤和FVII缺乏症的患者.
- 对导致FVII缺乏症的抑制剂或自身抗体的评估.
- 在抗瘤治疗前后评估FVII水平和凝血参数.
主要成果:
- 患者呈现出多细胞血,全身性巨细胞瘤和同时存在的FVII缺乏症.
- 没有将FVII缺乏归因于抑制剂或自身抗体.
- 在治疗血液瘤的抗瘤疗法后,FVII水平有所改善.
结论:
- 这一案例表明,系统性乳腺细胞瘤与血液瘤 (SM-AHN) 和获得的FVII缺乏症之间存在潜在的关联.
- 这些发现表明,病理性巨细胞可能会影响凝血因子度.
- 需要进一步的研究来阐明巨细胞瘤和凝血异常之间的关系.
相关概念视频
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.5K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
01:24Disorders of Hemostasis
885
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
885
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690